Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 28 |
| Active Pipeline (Recruiting Now) | 8 (6) |
| Completed vs Stopped Early | 18 / 2 (7.1%) |
| Median Closed Actual Enrollment | 176 participants |
| Physical Hospital Site Disclosure | 97.1% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 1 (1 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hokkaido University Hospital | Sapporo, Hokkaido | 2 |
| Yamagata University Hospital | Yamagata | 2 |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Otsuka Pharmaceutical Co Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.